MedTrace Logo

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

NCT01093326 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 353

Last updated 2025-03-30

Study results available
· View outcomes & findings →

Summary

This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.

Conditions

Interventions

DRUG

Ponesimod 10 mg

Ponesimod 10 mg oral use

DRUG

Ponesimod 20 mg

Ponesimod 20 mg oral use

DRUG

Ponesimod 40 mg

Ponesimod 40 mg oral use

Sponsors & Collaborators

  • Actelion

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-12
Primary Completion
2023-09-06
Completion
2023-09-06

Countries

  • United States
  • Austria
  • Bulgaria
  • Canada
  • Czechia
  • Finland
  • France
  • Germany
  • Hungary
  • Israel
  • Netherlands
  • Poland
  • Romania
  • Russia
  • Serbia
  • Spain
  • Sweden
  • Switzerland
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01093326 on ClinicalTrials.gov